Effect of selective LRRK2 kinase inhibition on nonhuman primate lung
0
Authors
Reina Fuji
Reina Fuji•Shannon Liu•Ryan Watts
Published
February 4, 2015
Abstract
LRRK2 kinase inhibitors, under development for Parkinson’s disease, have an effect on type II pneumocytes in nonhuman primate lung, suggesting that pulmonary toxicity may be a critical safety liability.
